Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 87.68 CHF 1.11% Market Closed
Market Cap: 171.5B CHF
Have any thoughts about
Novartis AG?
Write Note

Net Margin
Novartis AG

35.3%
Current
30%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35.3%
=
Net Income
17.6B
/
Revenue
49.9B

Net Margin Across Competitors

Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 754.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country US
Market Cap 151.5B USD
Net Margin
7%
Country IE
Market Cap 147.1B USD
Net Margin
-126%
No Stocks Found

Novartis AG
Glance View

Market Cap
171.5B CHF
Industry
Pharmaceuticals

Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.

NOVN Intrinsic Value
97.78 CHF
Undervaluation 10%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35.3%
=
Net Income
17.6B
/
Revenue
49.9B
What is the Net Margin of Novartis AG?

Based on Novartis AG's most recent financial statements, the company has Net Margin of 35.3%.